Nanotechnology: Intelligent Design to Treat Complex Disease
By P. Couvreur, C. Vauthier. Pharmaceutical Research, 2006
916 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/3d8f8d21379a17dda3b9bb99a2a8c86a81648047
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
- O. Farokhzad
- P. Couvreur
- Nariman Farsad
- S. Ganta
- H. Devalapally
- Huseyin Birkan Yilmaz
- Aliasgar F. Shahiwala
- M. Amiji
Citations in the corpus
- Nanocarriers as an emerging platform for cancer therapy. (2007, background): “Passive and active targeting Nanocarriers encounter numerous barriers en route to their target, such as mucosal barriers and non-specific uptak”
- A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, background): “Nanoparticulate carriers can be made from a variety of organic and inorganic materials including non-degradable and biodegradable polymers, lipids (liposomes, nanoemulsions, and solid-lipid nanoparticles) self-assembling amphiphilic molecules, dendrimers, metal, and inorganic semiconductor nanocryst”
- In situ forming implants - an attractive formulation principle for parenteral depot formulations. (2012, background): “Various types of parenteral dosage forms are available, such as solutions, emulsions [2], liposomes [3], micelles [4], implants [5], microparticles [6], nanoparticles and nanocapsules [7].”
- A Comprehensive Survey of Recent Advancements in Molecular Communication (2014, background): “inside the body provide significant improvements in diagnosis and treatment of diseases [94], [114], [115].”
- Nanoparticle vaccines. (2014, background): “arying in composition, size, shape, and surface properties, for pplication in the field of medicine [4,5].”
- Nanocarriers’ entry into the cell: relevance to drug delivery (2009, background): “After intravenous administration, PEGylation results in a decreased RES uptake and a prolonged circulation half-life, from typically a few minutes to several hours [41].”